These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 25679409

  • 41. Anti‑EGFR monoclonal antibody 134‑mG2a exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.
    Hosono H, Takei J, Ohishi T, Sano M, Asano T, Sayama Y, Nakamura T, Yanaka M, Kawada M, Harada H, Kaneko MK, Kato Y.
    Int J Mol Med; 2020 Oct; 46(4):1443-1452. PubMed ID: 32945346
    [Abstract] [Full Text] [Related]

  • 42. Targeted therapy of solid tumors by monoclonal antibody specific to epidermal growth factor receptor.
    Baradaran B, Majidi J, Farajnia S, Barar J, Omidi Y.
    Hum Antibodies; 2014 Oct; 23(1-2):13-20. PubMed ID: 25812698
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.
    Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J.
    Clin Cancer Res; 1995 Nov; 1(11):1311-8. PubMed ID: 9815926
    [Abstract] [Full Text] [Related]

  • 45. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
    Brezski RJ, Kinder M, Grugan KD, Soring KL, Carton J, Greenplate AR, Petley T, Capaldi D, Brosnan K, Emmell E, Watson S, Jordan RE.
    MAbs; 2014 Nov; 6(5):1265-73. PubMed ID: 25517311
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. [Predictive biomarkers of anti-EGFR monoclonal anti-body in colorectal cancer].
    Soeda H, Shimodaira H, Ishioka C.
    Gan To Kagaku Ryoho; 2011 Jul; 38(7):1079-83. PubMed ID: 21772090
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
    Martinelli E, Troiani T, Morgillo F, Rodolico G, Vitagliano D, Morelli MP, Tuccillo C, Vecchione L, Capasso A, Orditura M, De Vita F, Eckhardt SG, Santoro M, Berrino L, Ciardiello F.
    Clin Cancer Res; 2010 Oct 15; 16(20):4990-5001. PubMed ID: 20810384
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
    Zalba S, Contreras AM, Haeri A, Ten Hagen TL, Navarro I, Koning G, Garrido MJ.
    J Control Release; 2015 Jul 28; 210():26-38. PubMed ID: 25998052
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
    Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK, Ritter G, Old LJ, Burgess AW, Scott AM.
    Cancer Res; 2001 Jul 15; 61(14):5355-61. PubMed ID: 11454674
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Downregulation of EGFR by a novel multivalent nanobody-liposome platform.
    Oliveira S, Schiffelers RM, van der Veeken J, van der Meel R, Vongpromek R, van Bergen En Henegouwen PM, Storm G, Roovers RC.
    J Control Release; 2010 Jul 14; 145(2):165-75. PubMed ID: 20362020
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.